KR101201524B1 - 디벤조-р-디옥신 유도체를 포함하는 두피 및 모발 건강 개선용 조성물 - Google Patents
디벤조-р-디옥신 유도체를 포함하는 두피 및 모발 건강 개선용 조성물 Download PDFInfo
- Publication number
- KR101201524B1 KR101201524B1 KR1020100009811A KR20100009811A KR101201524B1 KR 101201524 B1 KR101201524 B1 KR 101201524B1 KR 1020100009811 A KR1020100009811 A KR 1020100009811A KR 20100009811 A KR20100009811 A KR 20100009811A KR 101201524 B1 KR101201524 B1 KR 101201524B1
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- formula
- scalp
- composition
- dibenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 110
- 210000004209 hair Anatomy 0.000 title abstract description 70
- 210000004761 scalp Anatomy 0.000 title abstract description 68
- 150000004827 dibenzo-1,4-dioxins Chemical class 0.000 title abstract description 14
- 230000006872 improvement Effects 0.000 title abstract description 4
- 230000036541 health Effects 0.000 title description 9
- 230000003779 hair growth Effects 0.000 claims abstract description 21
- 201000004384 Alopecia Diseases 0.000 claims abstract description 13
- 230000003676 hair loss Effects 0.000 claims abstract description 13
- 208000024963 hair loss Diseases 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 25
- 238000009472 formulation Methods 0.000 claims description 23
- NFBOHOGPQUYFRF-UHFFFAOYSA-N oxanthrene Chemical class C1=CC=C2OC3=CC=CC=C3OC2=C1 NFBOHOGPQUYFRF-UHFFFAOYSA-N 0.000 claims description 21
- 239000002453 shampoo Substances 0.000 claims description 16
- 230000001737 promoting effect Effects 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 10
- 230000003658 preventing hair loss Effects 0.000 claims description 8
- -1 rinse Substances 0.000 claims description 8
- 230000001256 tonic effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 208000001840 Dandruff Diseases 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 32
- 206010061218 Inflammation Diseases 0.000 abstract description 24
- 208000003251 Pruritus Diseases 0.000 abstract description 23
- 230000004054 inflammatory process Effects 0.000 abstract description 22
- 230000003646 hair health Effects 0.000 abstract description 21
- 230000006378 damage Effects 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 241000555676 Malassezia Species 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 238000011109 contamination Methods 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 230000003648 hair appearance Effects 0.000 abstract description 2
- 230000011506 response to oxidative stress Effects 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000000523 sample Substances 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 16
- 230000003110 anti-inflammatory effect Effects 0.000 description 15
- 230000007803 itching Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 13
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000012488 sample solution Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 239000000118 hair dye Substances 0.000 description 4
- 230000003699 hair surface Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001291477 Malassezia restricta Species 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000037389 hair physiology Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000008798 inflammatory stress Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000243681 Eisenia bicyclis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- PFTAWBLQPZVEMU-UHFFFAOYSA-N catechin Chemical compound OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
시료 | 모발 친화력 (%) |
DPPH 라디칼 소거 활성(%) | 항염효과(%) | 항균력(저해반경, mm) |
화학식1 | 66 | 87 | 72 | 6 |
화학식2 | 71 | 92 | 74 | 6 |
화학식3 | 72 | 93 | 85 | 6 |
화학식4 | 68 | 74 | 76 | 6 |
화학식5 | 82 | 88 | 82 | 10 |
화학식6 | 85 | 88 | 70 | 8 |
화학식7 | 83 | 87 | 74 | 8 |
화학식8 | 87 | 86 | 83 | 8 |
화학식9 | 65 | 78 | 73 | 6 |
화학식10 | 67 | 77 | 85 | 8 |
화학식5(R=acetyl): 화학식5(R=H)=3:7 | 54 | 72 | 71 | 5 |
화학식8(R=oleoyl): 화학식8(R=H)=1:9 | 73 | 83 | 77 | 7 |
화학식3(R=methyl): 화학식3(R=H)=2:8 | 67 | 72 | 70 | 6 |
Quercetin | 26 | 77 | 23 | 1 |
EGCG | 35 | 89 | 38 | 2 |
catechin | 21 | 75 | 18 | 0 |
살리실산 | 5 | 23 | 81 | 8 |
시료 | 시료의 조성 (화학식1내지 10에서 R=H이고, 하기 비율은 중량비임) |
조성물1 | 화학식3: 화학식5 : 화학식6: 화학식8 = 25:35:20:20 |
조성물2 | 화학식5: 화학식6: 화학식7: 화학식8 = 43:22:12:23 |
조성물3 | 화학식3: 화학식5: 화학식6: 화학식8: 화학식10 = 50:15:10:10:15 |
조성물4 | 화학식1: 화학식2: 화학식3: 화학식4: 화학식5: 화학식6: 화학식7: 화학식8: 화학식9: 화학식10 = 5:5:20:3:25:15:8:12:2:5 |
조성물5 | 화학식1: 화학식2: 화학식3: 화학식10 = 16:8:60:16 |
처리시료 | 새롭게 자란 모발 무게(mg) |
음성대조 | 22 ±19 |
조성물1 | 96 ±17 |
조성물2 | 88 ±15 |
조성물3 | 85 ±18 |
조성물4 | 90 ±17 |
조성물5 | 70 ±10 |
EGCG | 65 ±15 |
처리시료 | 귀 두께(㎛) | 발생빈도 |
음성대조군 | 402±32 | 9/10 |
조성물 1 | 264±21 | 3/10 |
조성물 2 | 284±26 | 3/10 |
조성물 3 | 271±24 | 5/10 |
조성물 4 | 268±30 | 4/10 |
조성물 5 | 287±19 | 4/10 |
EGCG | 350±26 | 6/10 |
처리시료 | 30분간 긁은 평균 횟수 |
음성대조군 | 180.6±15.3 |
조성물 1 | 130.2±16.3 |
조성물 2 | 126.2±15.6 |
조성물 3 | 135.2±14.9 |
조성물 4 | 125.3±21.3 |
조성물 5 | 120.5±19.2 |
EGCG | 160.3±16.3 |
성분(중량%) | 제형예1 | 비교예1 | 비교예2 |
에탄올 | 50.00 | 50.30 | 50.00 |
활성성분 | 0.30(조성물1) | 0.30(quercetin) | 0.30(EGCG) |
글리세린 | 3.00 | 3.00 | 3.00 |
실리실산 | 0.05 | 0.05 | 0.05 |
멘톨 | 0.02 | 0.02 | 0.02 |
정제수 | 46.63 | 46.63 | 46.63 |
성분(중량%) | 제형예2 | 비교예3 | 비교예4 |
정제수 | 50.74 | 50.74 | 50.74 |
활성성분 | 0.15(조성물1) | 0.15(살리실산) | 0.15(EGCG) |
Sodium Laureth Sulfate | 36.00 | 36.00 | 36.00 |
Cocamidopropyl Betaine | 8.00 | 8.00 | 8.00 |
프로필렌글리콜 | 2.00 | 2.00 | 2.00 |
글라이콜디스테아레이트 | 1.50 | 1.50 | 1.50 |
정제염 | 1.00 | 1.00 | 1.00 |
Polyquaternium-7 | 0.50 | 0.50 | 0.50 |
구연산 | 0.10 | 0.10 | 0.10 |
향료 | 0.01 | 0.01 | 0.01 |
성분(중량%) | 제형예3 |
정제수 | 89.09 |
조성물2 | 0.20 |
프로틸렌글리콜 | 2.00 |
세틸트리메틸암모늄클로라이드 | 1.00 |
세틸알코올 | 3.00 |
스테아릴알코올 | 3.00 |
미네랄오일 | 0.50 |
구연산 | 0.20 |
폴리디메틸실록산 | 1.00 |
향료 | 0.01 |
성분(중량%) | 제형예4 |
정제수 | 92.14 |
조성물4 | 0.15 |
세토스테아릴알코올 | 2.00 |
Disoudium EDTA | 0.20 |
히드록시에틸셀룰로오즈 | 0.50 |
미네랄오일 | 5.00 |
향료 | 0.01 |
처리군 | 탈락모 개수 |
제형예 1 | 50 |
비교예 1 | 80 |
비교예 2 | 75 |
그룹 | 평균감소율(%) | 비듬방지효과 있다 | 비듬방지효과 없다 | 잘 모르겠다 | 피시험자수 |
제형예2 | 30.2 | 5 | 2 | 3 | 10 |
비교예3 | 15.3 | 1 | 5 | 4 | 10 |
비교예4 | 12.6 | 2 | 5 | 3 | 10 |
평가 구분(가려움증 감소 효과) | 평점 |
매우있다 | 5 |
있다 | 4 |
보통이다 | 3 |
없다 | 2 |
전혀없다 | 1 |
제형 | 두피가려움 억제 효과 |
제형예2 | 4.5 |
비교예3 | 3.2 |
비교예4 | 2.8 |
Claims (12)
- 삭제
- 삭제
- 삭제
- 청구항4에 있어서, 상기 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체는, 상기 유도체 총 중량에 대하여 화학식3의 화합물 10~60 중량%, 화학식5의 화합물 15~60 중량%, 화학식6의 화합물 10~40 중량% 및 화학식8의 화합물 5~30 중량%를 포함하여 구성되는 것을 특징으로 하는 탈모 방지 및 모발의 생장촉진용 화장료 조성물.
- 청구항6에 있어서, 상기 화학식1, 화학식2, 화학식4, 화학식9 및 화학식10으로 표시되는 화합물로 이루어진 군으로부터 선택되는 1종 이상의 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체는 조성물에 포함되는 전체 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체 총 중량에 대하여 0.1~50 중량%로 포함되는 것을 특징으로 하는 탈모 방지 및 모발의 생장촉진용 화장료 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 청구항4 내지 청구항7 중의 어느 한 항에 있어서, 샴푸, 린스, 로션, 토닉, 에센스, 비누, 젤 및 무스로 이루어진 군으로부터 선택되는 제형으로 제조되는 것을 특징으로 하는 탈모 방지 및 모발의 생장촉진용 화장료 조성물.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100009811A KR101201524B1 (ko) | 2010-02-03 | 2010-02-03 | 디벤조-р-디옥신 유도체를 포함하는 두피 및 모발 건강 개선용 조성물 |
PCT/KR2011/000654 WO2011096688A2 (ko) | 2010-02-03 | 2011-01-31 | 디벤조-р-디옥신 유도체를 포함하는 두피 및 모발 건강 개선용 조성물 |
JP2012551913A JP5694382B2 (ja) | 2010-02-03 | 2011-01-31 | ジベンゾ−p−ジオキシン誘導体を含む脱毛防止および毛髪の生長促進用組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100009811A KR101201524B1 (ko) | 2010-02-03 | 2010-02-03 | 디벤조-р-디옥신 유도체를 포함하는 두피 및 모발 건강 개선용 조성물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120031293A Division KR101220508B1 (ko) | 2012-03-27 | 2012-03-27 | 디벤조-р-디옥신 유도체를 포함하는 두피 및 모발 건강 개선용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110090174A KR20110090174A (ko) | 2011-08-10 |
KR101201524B1 true KR101201524B1 (ko) | 2012-11-14 |
Family
ID=44355936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100009811A Active KR101201524B1 (ko) | 2010-02-03 | 2010-02-03 | 디벤조-р-디옥신 유도체를 포함하는 두피 및 모발 건강 개선용 조성물 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP5694382B2 (ko) |
KR (1) | KR101201524B1 (ko) |
WO (1) | WO2011096688A2 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10004678B2 (en) * | 2013-08-22 | 2018-06-26 | Lucas Meyer Cosmetics Canada Inc. | Anti-dandruff compositions, and methods of use thereof |
CN109276466A (zh) * | 2017-07-21 | 2019-01-29 | 博塔医疗株式会社 | 以褐藻多酚为有效成分的用于防止白发及促进黑发的组合物及产品 |
KR102192712B1 (ko) * | 2018-01-25 | 2020-12-18 | 주식회사 헤마스 | 플로로탄닌을 유효성분으로 포함하는 동물사료용 조성물 및 동물용 제품 |
WO2020116890A1 (ko) * | 2018-12-05 | 2020-06-11 | 주식회사 보타메디 | 플로로탄닌을 유효성분으로 포함하는 음식 향미 개선용 조성물 |
KR102144990B1 (ko) * | 2019-04-24 | 2020-08-14 | 한국과학기술연구원 | 아크릴레이트 화합물, 그 고분자 및 이를 포함하는 폴리아크릴레이트 필름 |
CN111018874B (zh) * | 2019-11-25 | 2021-06-22 | 武汉华星光电半导体显示技术有限公司 | 空穴传输材料、其制备方法及有机发光二极管器件 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100879558B1 (ko) * | 2007-07-31 | 2009-01-22 | 라이브켐 주식회사 | 디벤조파라디옥신 유도체를 유효성분으로 함유한 피부보호 및 개선제 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3652382B2 (ja) * | 1994-04-11 | 2005-05-25 | 株式会社ナリス化粧品 | テストステロン−5α−レダクターゼ阻害剤 |
KR100363112B1 (ko) * | 2000-04-27 | 2002-12-05 | 벤트리 주식회사 | 감태로부터 분리된 신규 물질, 이의 추출 및 정제방법, 및항산화제로 사용하는 용도 |
KR20020025358A (ko) * | 2000-09-28 | 2002-04-04 | 이 행 우 | 발모 조성물 및 이의 제조 방법 |
JP2007131571A (ja) * | 2005-11-10 | 2007-05-31 | Ichimaru Pharcos Co Ltd | 毛乳頭細胞増殖促進剤 |
JP2007217339A (ja) * | 2006-02-16 | 2007-08-30 | Kanehatsu Foods Co Ltd | 抗アレルギー物質 |
JP2010013429A (ja) * | 2008-07-01 | 2010-01-21 | Takashi Suzuki | 頭皮外用剤 |
-
2010
- 2010-02-03 KR KR1020100009811A patent/KR101201524B1/ko active Active
-
2011
- 2011-01-31 WO PCT/KR2011/000654 patent/WO2011096688A2/ko active Application Filing
- 2011-01-31 JP JP2012551913A patent/JP5694382B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100879558B1 (ko) * | 2007-07-31 | 2009-01-22 | 라이브켐 주식회사 | 디벤조파라디옥신 유도체를 유효성분으로 함유한 피부보호 및 개선제 |
Also Published As
Publication number | Publication date |
---|---|
JP2013518875A (ja) | 2013-05-23 |
JP5694382B2 (ja) | 2015-04-01 |
WO2011096688A3 (ko) | 2012-01-05 |
WO2011096688A2 (ko) | 2011-08-11 |
KR20110090174A (ko) | 2011-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101201524B1 (ko) | 디벤조-р-디옥신 유도체를 포함하는 두피 및 모발 건강 개선용 조성물 | |
KR101402417B1 (ko) | 천연물 유래 필로바시디움 억제 물질을 포함하는 항균용 조성물 | |
KR102475897B1 (ko) | 그라비올라 항균 추출물을 함유하는 화장료 조성물 및 그 제조방법 | |
KR102429343B1 (ko) | 복합 생약 추출물 유효성분으로 포함하는 두피 및 모발개선용 화장료 조성물. | |
KR20110085371A (ko) | 천연식물 추출물을 함유한 두피 상태 개선용 화장료 조성물 | |
KR101464914B1 (ko) | 피부 장벽 강화와 세포 재생으로 여드름을 치료하는 조성물 및 그 제조 방법 | |
KR101220508B1 (ko) | 디벤조-р-디옥신 유도체를 포함하는 두피 및 모발 건강 개선용 조성물 | |
KR101530415B1 (ko) | 굴피나무 추출물을 유효성분으로 함유하는 탈모 방지 또는 발모 촉진용 조성물 | |
JP4906179B2 (ja) | 皮膚外用剤 | |
KR101587446B1 (ko) | 아임계추출조건으로 추출한 추출물 il-s를 포함하는 항균, 보습, 가려움개선, 세라마이드증가, 항염 효과를 지닌 화장료 조성물 | |
KR102824757B1 (ko) | 라벤더잎세포추출물을 유효성분으로 포함하는 외부 자극에 의한 피부 장벽개선 및 피부 진정(붉은기)에 효과적인 조성물 | |
KR101252554B1 (ko) | 피지분비 억제용 조성물 | |
KR20210009178A (ko) | 천마추출물을 포함하는 조성물 | |
KR101396275B1 (ko) | 피부 미백 효과가 있는 강진향 추출물 | |
ES2982569T3 (es) | Combinación de ciclopiroxolamina y piroctona olamina para combatir la caspa | |
KR100682979B1 (ko) | 항균 감염증 및 항염증 작용에 대한 예방 치료용 조성물 및이를 이용하여 얻어진 무좀치료제 | |
WO2019009663A1 (ko) | 무좀 예방 및 개선용 조성물 | |
JPH03112912A (ja) | 化粧料組成物 | |
KR102297607B1 (ko) | 며느리배꼽을 포함하는 아토피 피부 개선 및 피부 보습용 조성물 | |
KR20050117409A (ko) | 비듬 방지용 모발 화장료 조성물 | |
KR102676799B1 (ko) | 천연 복합 추출물 함유 피부 개선용 외용제 조성물 | |
KR20210068936A (ko) | 천연물을 포함하는 아토피성 피부 개선 및 피부 보습용 조성물 | |
KR102428010B1 (ko) | 피부외용제 조성물 | |
KR102540960B1 (ko) | 무화과 효소를 포함하는 항균용 조성물 | |
KR20130133387A (ko) | 항균 및 항산화 효과를 가지는 세정제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20100203 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20111127 Patent event code: PE09021S01D |
|
A107 | Divisional application of patent | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20120327 Patent event code: PA01071R01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20120824 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20121108 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20121109 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20151109 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20151109 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20161108 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20161108 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20171208 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20171208 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20181108 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20181108 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20191101 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20201109 Start annual number: 9 End annual number: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20211108 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20221108 Start annual number: 11 End annual number: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20231108 Start annual number: 12 End annual number: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20250108 Start annual number: 13 End annual number: 13 |